152 related articles for article (PubMed ID: 37530663)
1. Renal cell carcinoma with non-clear cell histologies: all the same peas in one pod?
Roussel E; Amparore D; Bertolo R; Erdem S; Marchioni M; Pavan N; Campi R;
Minerva Urol Nephrol; 2023 Aug; 75(4):529-531. PubMed ID: 37530663
[No Abstract] [Full Text] [Related]
2. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies.
Dutcher JP; de Souza P; McDermott D; Figlin RA; Berkenblit A; Thiele A; Krygowski M; Strahs A; Feingold J; Hudes G
Med Oncol; 2009; 26(2):202-9. PubMed ID: 19229667
[TBL] [Abstract][Full Text] [Related]
3. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.
Martínez Chanzá N; Xie W; Asim Bilen M; Dzimitrowicz H; Burkart J; Geynisman DM; Balakrishnan A; Bowman IA; Jain R; Stadler W; Zakharia Y; Narayan V; Beuselinck B; McKay RR; Tripathi A; Pachynski R; Hahn AW; Hsu J; Shah SA; Lam ET; Rose TL; Mega AE; Vogelzang N; Harrison MR; Mortazavi A; Plimack ER; Vaishampayan U; Hammers H; George S; Haas N; Agarwal N; Pal SK; Srinivas S; Carneiro BA; Heng DYC; Bosse D; Choueiri TK; Harshman LC
Lancet Oncol; 2019 Apr; 20(4):581-590. PubMed ID: 30827746
[TBL] [Abstract][Full Text] [Related]
4. Management of non-clear cell renal cell carcinoma: Current approaches.
Tsimafeyeu I
Urol Oncol; 2017 Jan; 35(1):5-13. PubMed ID: 27544302
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy for non-clear-cell renal cell carcinoma.
David KA; Milowsky MI; Nanus DM
Clin Genitourin Cancer; 2006 Mar; 4(4):263-8. PubMed ID: 16729909
[TBL] [Abstract][Full Text] [Related]
6. Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical data.
Barthélémy P; Rioux-Leclercq N; Thibault C; Saldana C; Borchiellini D; Chevreau C; Desmoulins I; Gobert A; Hilgers W; Khalil A; Lemoine N; Schlürmann-Constans F; Négrier S
Cancer Treat Rev; 2021 Jun; 97():102191. PubMed ID: 34015728
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapies for non-clear renal cell carcinoma.
Singer EA; Bratslavsky G; Linehan WM; Srinivasan R
Target Oncol; 2010 Jun; 5(2):119-29. PubMed ID: 20680492
[TBL] [Abstract][Full Text] [Related]
8. Renal-cell carcinoma.
Cohen HT; McGovern FJ
N Engl J Med; 2005 Dec; 353(23):2477-90. PubMed ID: 16339096
[No Abstract] [Full Text] [Related]
9. Do tyrosine kinase inhibitors lose favor in treatment of first-line metastatic renal cell carcinoma?
Yaman S; Bilgin B; Şendur MA; Hızal M; Akıncı MB; Yalçın B
Future Oncol; 2019 Mar; 15(9):925-927. PubMed ID: 30854890
[No Abstract] [Full Text] [Related]
10. Neoadjuvant temsirolimus effectiveness in downstaging advanced non-clear cell renal cell carcinoma.
Rodríguez Faba O; Breda A; Rosales A; Palou J; Algaba F; Maroto Rey P; Villavicencio H
Eur Urol; 2010 Aug; 58(2):307-10. PubMed ID: 20347211
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma.
Molina AM; Feldman DR; Ginsberg MS; Kroog G; Tickoo SK; Jia X; Georges M; Patil S; Baum MS; Reuter VE; Motzer RJ
Invest New Drugs; 2012 Feb; 30(1):335-40. PubMed ID: 20711632
[TBL] [Abstract][Full Text] [Related]
12. One decade of improving palliative care of metastatic renal cell carcinoma by antiangiogenic therapies: time to move toward RCC cure.
Kroeger N; Zimmermann U; Burchardt M
Int J Cancer; 2015 Apr; 136(7):1483-4. PubMed ID: 25230294
[No Abstract] [Full Text] [Related]
13. Sarcomatoid renal cell carcinoma.
Akhtar K; Shamshad A; Sufian Z; Tariq M
Saudi J Kidney Dis Transpl; 2011 Jan; 22(1):120-2. PubMed ID: 21196626
[TBL] [Abstract][Full Text] [Related]
14. Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents.
Coinu A; Petrelli F; Barni S
Expert Rev Anticancer Ther; 2016; 16(1):33-43. PubMed ID: 26535485
[TBL] [Abstract][Full Text] [Related]
15. Pituitary metastasis from a renal cell carcinoma progressed after sorafenib treatment.
Yang L; Yu SY; Hu GY
Chin J Cancer; 2013 Jun; 32(6):353-6. PubMed ID: 23237217
[TBL] [Abstract][Full Text] [Related]
16. Renal cell carcinoma presenting with vaginal metastasis.
Griffin SJ; Loftus B; McDermott TE; Grainger R
Ir Med J; 2003 Apr; 96(4):115-6. PubMed ID: 12793475
[No Abstract] [Full Text] [Related]
17. [Nivolumab combined with ipilimumab versus sunitinib monotherapy-SUNNIFORECAST AN 41/16 of the AUO : A phase 2, randomized, open-label study in subjects with previously untreated and advanced (unresectable or metastatic) non-clear cell renal cell carcinoma].
Rexer H; Steiner T; Bergmann L
Urologe A; 2017 Jun; 56(6):802-803. PubMed ID: 28536740
[No Abstract] [Full Text] [Related]
18. Evolving treatment landscape in metastatic renal cell carcinoma: where are we now?
Procopio G; Ratta R; Grassi P
Expert Rev Anticancer Ther; 2016; 16(2):133-5. PubMed ID: 26654053
[No Abstract] [Full Text] [Related]
19. New approaches in advanced renal cell carcinoma.
Rini BI
Urol Oncol; 2005; 23(1):65-6. PubMed ID: 15885585
[No Abstract] [Full Text] [Related]
20. An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC).
D'Angelo A; Bagby S; Di Pierro G; Chirra M; Nobili S; Mini E; Villari D; Roviello G
Crit Rev Oncol Hematol; 2020 May; 149():102921. PubMed ID: 32172222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
